Applications of hydrogels in microfluidic devices

Hydrogels are water-rich, cross-linked polymer networks — made from natural materials like collagen, synthetic polymers like PEG, or blends like GelMA — prized for biocompatibility and tunable mechanical properties that let them mimic native extracellular matrix. Their use in microfluidics has grown fast: published research on the topic rose from around 4,000 papers in 2017 to over 6,500 in 2021, and keeps climbing.

The field traces back to 1960, when Wichterle and Lim introduced the first hydrogel for biological use. Early research through the 1990s focused on wound dressings and drug delivery; once microfluidic devices emerged as a research tool in the late '90s and 2000s, hydrogels and microfluidics began to merge, culminating in cell-laden microfluidic hydrogels by 2007 and today's organ-on-a-chip platforms.

Four fabrication approaches dominate the field, each suited to different device geometries and throughput needs.

Current research clusters into four categories: 2D and 3D flow cell culture, drug delivery, and sensors. A University of Wisconsin–Madison team, for example, used PEG-encapsulated hydrogels to model the tumor microenvironment in glioblastoma cells under controlled perfusion — capturing diffusion-limited drug transport that a flat Petri dish can't replicate.

On the drug delivery side, a University of British Columbia group built an implantable system using thermo-reactive hydrogel microvalves triggered wirelessly by radio frequency — releasing drugs on demand without any onboard power supply.

Sensing applications range from pH-responsive photonic crystal beads to hydrogel-immobilized enzymes that detect glucose and galactose in real time — all leveraging the same core property: a hydrogel's structure changes measurably in response to its chemical environment.

The two biggest limitations we identified are fabrication difficulty and infrastructure cost. Molds don't allow fine spatial control; 3D bioprinting offers better resolution but suffers from scalability and reproducibility issues. On top of that, the cleanroom and cell-culture infrastructure needed to support this research is expensive to build and maintain.